Core Viewpoint - Wanbang Pharmaceutical's stock closed at 41.95 yuan, marking a 2.04% increase, with a rolling PE ratio of 41.31, the lowest in 39 days, and a total market capitalization of 2.797 billion yuan [1] Company Summary - Wanbang Pharmaceutical specializes in providing professional pharmaceutical research and development outsourcing services to pharmaceutical companies and other R&D institutions [1] - The company's main products include clinical trial site management (SMO), biological sample analysis (BA), data management and statistical analysis (DM/ST), prescription process research, quality research, and stability research [1] - For Q1 2025, the company reported operating revenue of 71.0522 million yuan, a year-on-year decrease of 21.20%, and a net profit of 11.8493 million yuan, down 60.09%, with a gross profit margin of 31.62% [1] Industry Summary - The average PE ratio for the medical services industry is 40.35, with a median of 47.21, placing Wanbang Pharmaceutical at 29th in the industry ranking [2] - As of Q1 2025, three institutions hold shares in Wanbang Pharmaceutical, with a total of 1.5205 million shares valued at 6.2 million yuan [1]
万邦医药收盘上涨2.04%，滚动市盈率41.31倍，总市值27.97亿元